Today

Agents

Chat

Arena

Discover

More

App

Onconetix subsidiary Proteomedix names co-founder Ralph Schiess to board - ONCO News | Rallies

Onconetix subsidiary Proteomedix names co-founder Ralph Schiess to board

ONCO•2026-08-05

Proteomedix appoints co-founder to board

Onconetix subsidiary Proteomedix appointed co-founder Ralph Schiess to its board.
Shareholders re-elected Thomas Meier as board chairman for a one-year term at the June 22 annual meeting.
The move adds Proclarix co-developer Schiess as Proteomedix advances its CE-IVD prostate cancer blood test.

Related News

Entegris Inc <ENTG.O>: UBS Raises Target Price to $215 From $205

ENTG•2026-08-05

Arista Networks Inc <ANET.N>: UBS Raises Target Price to $259 From $187

ANET•2026-08-05

IDEXX Laboratories Inc <IDXX.O>: UBS raises target price to $670 from $620

2026-08-05

Cabot Corp <CBT.N>: UBS Cuts Target Price To $92 From $97

CBT•2026-08-05

China SXT Pharmaceuticals plans 1-for-80 share consolidation effective Aug. 10

SXTC•2026-08-05